Drug interactions at the renal level: Implications for drug development

Clinical Pharmacokinetics

Volumn 34, Issue 5, 1998, Pages 375-404

  Bonate, Peter L ^a   Reith, Kelly ^a   Weir, Scott ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; AMILORIDE; CEPHALOSPORIN; CIMETIDINE; DIDANOSINE; EPHEDRINE; FUROSEMIDE; LAMIVUDINE; METHADONE; METHOTREXATE; MORPHINE; PENICILLIN G; PROBENECID; PROCAINAMIDE; RANITIDINE; SALICYLIC ACID; SULFAMETHOXAZOLE; TRIMETHOPRIM; ZALCITABINE; ZIDOVUDINE;

DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG INFORMATION; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOXICITY; GLOMERULUS FILTRATION; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MICHAELIS MENTEN KINETICS; MICTURITION; NONHUMAN; PKA; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION; URINE PH;

ANIMALS; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; KIDNEY; MODELS, BIOLOGICAL; PHARMACOKINETICS;

EID: 0031947633     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834050-00004     Document Type: Review

References (128)

1. Vander AJ, Sherman JH, Luciano DS. Human physiology. New York: McGraw-Hill, 1990
2. Narayanan S. Renal biochemistry and physiology: pathophysiology and analytical perspectives. Adv Clin Chem 1992; 29: 121-59
3. Vickers AEM, Fischer V, Connors MS, et al. Biotransformation of the antiemetic 5-HT3 antagonist tropisetron in liver and kidney slices of human, rat, and dog with a comparison to in vivo. Eur J Drug Metab Pharmacokinet 1996; 21: 43-50
4. van Acker BA, Koomen GC, Koopman MG, et al. Discrepancy between circadian rhythms of inulin and creatinine clearance. J Lab Clin Med 1992; 120: 400-10
5. Koopman MG, Koomen GC, Krediet RT, et al. Circadian rhythm of glomerular filtration rate in normal individuals. Clin Sci 1989; 77: 105-11
6. Williams LR, Leggett RW. Reference values for resting blood flow to organs of man. Clin Phys Physiol Meas 1989; 10: 187-217
7. West JB, editor. Best and Taylor's physiological basis of medical practice. 11th ed. Baltimore: Williams & Wilkins, 1985
8. Waddell WJ, Butler TC. The distribution and excretion of phenobarbital. J Clin Invest 1957; 36: 1217-26
9. Lindberg MC, Cunningham A, Lindberg NH. Acute phenobarbital intoxication. South Med J 1992; 85: 803-7
10. Besseghir K, Roch-Ramel F. Renal excretion of drugs and other xenobiotics. Renal Physiol 1987; 10: 221-41
11. Moller JV, Skeikh MI. Renal organic anion transport system: pharmacological, physiological, and biochemical aspects. Pharmacol Rev 1983; 34: 315-58
12. Pritchard JB, Miller DS. Comparative insights into the mechanisms of renal organic anion and cation secretion. Am J Physiol 1991; 261: R1329-40
13. Brown GR. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet 1993; 24: 289-300
14. Handsfield HH. Recent developments in gonorrhea and pelvic inflammatory disease. J Med 1983; 14: 281-305
15. Speeg KV, Leighton JV, Maldonado AL. Toxic delerium in a patient taking amanladine and trimethoprim/sulfamethoxazole. Am J Med Sci 1989; 298: 410-2
16. Robinson PJ, Rapoport SI. The kinetics of protein binding determine the rate of uptake of drugs by the brain. Am J Physiol 1986; 251: R1212-20
17. Inoue M, Okajima K, Ando Y, et al. Mechanism of furosemide resistance by analbumininemic rats and hypoalbuminemic patients. Kidney Int 1987; 32: 198-203
18. Smith HW. Lectures on the kidney. Lawrence: University of Kansas, 1943
19. Ullrich KJ, Rumrich G. Contraluminal transport systems in the proximal renal tubules involved in secretion of organic ions. Am J Physiol 1988; 254: F453-62
20. Burkhardt G, Ullrich KJ Organic anion transport across the Contraluminal membrane KJ dependence on sodium. Kidney Int 1989; 36: 370-7
21. Spencer AM, Sack J, Hong SK. Relationship between PAH transport and Na-K-ATPase activity in the rabbit kidney. Am J Physiol 1979; 236: F126-30
22. Dantzler WH. K+ effects on PAH transport and permeabilities in isolate snake renal tubules. Am J Physiol 1974; 227: 1361-70
23. Dantzler WH, Brokl OH. Effects of low [Ca2+] and La[3+] on PAH transport by isolated perfused renal tubules. Am J Physiol 1984; 246: F175-87
24. Somogyi A, Gugler R. Drug interactions with cimetidine. Clin Pharmacokinet 1982; 7: 23-41
25. Rennick BR. Renule tubule transport of organic cations. Am J Physiol 1981; 240: F83-9
26. Kinsella JL, Holohan PD, Pessah NI, et al. Transport of organic ions in renal cortical luminal and anitluminal membrane vesicles. J Pharmacol Exp Ther 1979; 209: 443-50
27. van Crugten J, Bochner F, Keal J, et al. Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J Pharmacol Exp Ther 1986; 236: 481-7
28. Gower PE, Dash CH. Cephalexin, human studies of absorption and excretion of a new cephalosproin antibiotic. Br J Pharmacol 1969; 37: 738-47
29. Carr RA, Pasutto FM, Foster RT. Infleunce of cimetidine coadministration on the pharmacokinetics of sotalol enantiomers in an anesthetized rat model: evidence supporting active renal excretion of sotalol. Biopharm Drug Dispos 1996; 17: 55-69
30. Litterst CL, Mimnaugh EG, Reagan RL, et al. Comparison of in vitro drug metabolism by the lung, liver, and kidney of several common laboratory species. Drug Metab Dispos 1975; 3: 259-65
31. Vree TB, Hekster YA, Anderson PG. Contribulion of the human kidney to the metabolic clearance of drugs. Ann Pharmacother 1992; 26: 1421-8
32. 4-acetylation of sulfa-6-monomethoxine in humans. Pharm Weekbl Sci 1990; 12: 71-5
33. 4-acetylation of sulfamethomidine in humans. Pharm Weekbl Sci 1991; 13: 198-206
34. 4-acelylation of sulfa-6-monomethoxine in humans. Drug Metab Dispos 1990; 18: 852-8
35. Mazoit JX, Sandouk P, Schermann JM, et al. Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther 1990; 48: 613-8
36. Howe JL, Back DJ, Colbert J. Extrahepatic metabolism of zidovudine. Br J Clin Pharmacol 1992; 33: 190-2
37. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144-60
38. Bendayan R. Renal drug transport: a review. Pharmacotherapy 1996; 16: 971-85
39. Gatmaitan ZC, Arias IM. Structure and function of p-glycoprotein in normal liver and small intestine. Adv Pharmacol 1993; 24: 77-97
40. Dudley A, Brown C. Mediation of cimetidine secretionby p-glycoprotein and a novel H+ - couple mechanism in cultured renal epithilial monolayers of LLC-PK1 cells. Br J Pharmacol 1996; 117: 1139-44
41. Charuk J, Wong P, Reithmeier R. Differential interaction of human renal p-glycoprotein with various metabolites and analogues of cyclosporin A. Am J Physiol 1995; 269: F31-9
42. Tucker GT. Measurement of the renal clearance of drugs. Br J Clin Pharmacol 1981, 12: 761-70
43. Martin BK. Drug urinary excretion data: some aspects concerning interpretation. Br J Pharmacol 1967; 29: 181-93
44. Roy T. Fitting a straight line when both variables are subject to error: pharmaceutical applications. J Pharm Biomed Anal 1994; 12: 1265-9
45. Reilman MA, Gunst RHm Lakshminarayanan MY. Stochastic regression with errors in both variables. J Qual Technol 1986; 18: 162-9
46. Levy G. Effect of plasma protein binding on renal clearance of drugs. J Pharm Sci 1980; 69: 482-3
47. Brisker NS, Klahr S, Lubowitz H, et al. Renal function in chronic renal disease. Medicine 1965; 44: 263-88
48. Dixon M, Webb EC. Enzymes. 3rd ed. New York: Academic Press, 1974
49. Gyory AZ, Lingard JM. Kinetics of active sodium transport in rat proximal tubules and its variation by cardiac glycosides at zero net volume and ion fluxes: evidence for a multisite sodium transport system. J Physiol 1976; 257: 257-74
50. Hekman P, van Kineken CA. Simultaneous kinetic modelling of plasma levels and urinary excretion of salicyluric acid, and the influence of probenecid. Eur J Drug Metab Pharmacokinet 1983; 8: 239-49
51. Upton RA, Williams RL, Bushkin JN, et al. Effects of probenecid on ketoprofen pharmacokinetics. Clin Pharmacol Ther 1982; 31: 705-12
52. van Ginneken CAM, Russel FGM. Saturable pharmacokinetics in the renal excretion of drugs. Clin Pharmacokinet 1989; 16: 38-54
53. Bekeisky I. The isolated perfused kidney as a pharmacological tool. Trends Pharmacol Sci 1983; 4: 6-7
54. Viekers AEM, Fischer V, Connors S, et al. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Ortig Metab Dispos 1992; 20: 802-9
55. Connors MS, Larrauri A, Dannecker R, et al. Biotransformation of a somatostatin analogue in precision-cut liver and kidney slices from rat, dog, and man. Xenobiotica 1996; 26: 133-41
56. Siebe H, Baude G, Lichtenstein I, et al. Metabolism of dexamethasone: sites and activity in mammalian tissues. Renal Physiol Biochem 1993; 16: 79-88
57. Lensmeyer GL, Wiebe AA, Carlson IH, et al. Concentrations of cyclosporin A and its metabolites in human tissue postmortem. J Anal Toxicol 1991; 15: 110-5
58. Nelson JA, Santos G, Herbert BH. Mechanisms for the renal secretion of cisplatin. Cancer Treat Rep 1984; 68: 849-53
59. Spector R. Riboflavin transport by rabbit kidney slices: characterization and relation to cyclic organic acid transport. J Pharmacol Exp Ther 1982; 221: 394-8
60. Ott RJ, Hui AC, Yuan G, et al. Organic cation transport in human renal brush-border membrane vesicles. Am J Physiol 1991; 261: F443-51
61. Hassal CD, Gandolfi AJ, Brendel K. Correlation of the in vivo and in vitro renal toxicity of S-(1,2-dichlorovinyl)-L-cysteine. Drug Chem Toxicol 1983; 6: 507-20
62. Jaffe DR, Hassall CD, Brendel K, et al. In vivo and in vitro nephrotoxicity of the cysteine conjugate of hexachlorobutatliene. J Toxicol Environ Health 1983; 11: 857-67
63. Okudaira N, Sugiyama Y. Use of an isolated perfused kidney to assess renal clearance of drugs. In: Borchardt RT, editor. Models for assessing drug absorption and metabolism. New York: Plenum Press, 1996: 211-38
64. Brett CM, Washington CB, Ott RJ, et al. Interaction of nucleoside analogues with the sodium-nucleoside transport system in brush border membrane vesicles from human kidney. Pharm Res 1993; 10: 423-6
65. Gutierrez MM, Giacomini KM. Substrate selectivity, potential sensitivity and stoichiometry of Na+ -nucleoside transport in brush border membrane vesicles from human kidney. Biochim Biophys Acta 1993; 1149: 202-8
66. Gutierrez MM, Brett CM, Ott RJ, et al. Nucleoside transport in brush border membrane vesicles from human kidney. Biochim Biophys Acta 1992; 1105: 1-9
67. Vijayalakshmi D, Belt JA. Sodium-dependent nucleoside transport in mouse intestinal epithelial cells: two transport systems with differing substrate specificities. J Biol Chem 1988; 263: 19419-23
68. Lee CW, Chesseman CI, Jarvis SM. Transport characteristics of renal brush border Na+- and K+-dependent uridine carriers. Am J Physiol 1990; 258: F1203-10
69. Bekersky I. Use of the isolated perfused kidney as a tool in drug disposition studies. Drug Metab Rev 1983; 14: 931-60
70. Maack T. Renal clearance and isolated perfusion techniques. Kidney Int 1986; 30: 142-51
71. Boom SPA, Moons MM, Russel FGM. Renal tubular Iransport of cimetidine in lhe isolated perfused kidney in the rat. Drug Metab Dispos 1994; 22: 148-53
72. Wan S, Riegelman S. Renal contribution to overall metabolism of drugs. II: biotransformation of salicylic acid to salicyluric acid. J Pharm Sci 1972; 61: 1284-7
73. Ahn H, Jamali F, Cox SR, et al. Stereoselective disposition of ibuprofen enantiomers in the isolated perfused rat kidney. Pharm Res 1991; 8: 1520-4
74. de Lennoy IAM, Hirayama H, Pang KS. A physiological model for renal drug metabolism: enalapril esterolysis to enalaprilat in the isolated perfused kidney. J Pharmacokinet Biopharm 1990; 18: 561-87
75. McElnay JC, D'Arcy PF. Sites and mechanisms of drug interactions. II: protein binding, renal excretion and pharmacodynamic interactions. Int J Pharm 1980; 6: 205-23
76. Martin SW, Broadley KJ. Renal vasodilatation by dopexamine and fenoldapam due to a1-adrenoceptor blockade. Br J Pharmacol 1995; 115: 349-55
77. Li T, Croce K, Winquist RJ. Vasocontrictor and vasodilator effects of serotonin in the isolated rabbit kidney. J Pharmacol Exp Ther 1992; 263: 928-32
78. Castellucci A, Maggi CA, Evangelista S. Calcitonin gene-related peptide (CGRP)1 receptor mediates vasodilation in the rat isolated and perfused kidney. Life Sci 1993; 53: 153-8
79. Smith DE, Guillard S, Rodriguez CA. Effect of angiotensin II-induced changes in perfusion flow rate on chlorothiazide transport in the isolated perfused kidney. J Pharmacokinet Biopharm 1992; 20: 19.5-207
80. Lee L, Cook JA, Smith DE. Renal transport kinetics of chlorothiazide in the isolated perfused kidney. J Pharmacol Exp Ther 1988; 247: 20.3-8
81. Lee L, Cook JA, Smith DE. Renal transport kinetics of furosemide in the isolated perfused kidney. J Pharmacokinet Biopharm 1986; 14: 157-74
82. Rodriguez CA, Smith DE. Influence of the unbound concentration of cefonicid on its renal elimination in isolated perfused rat kidneys. Antimicrob Agents Chemother 1991; 35: 2395-400
83. Sweeney KR, Hsyu P, Statkevich P, et al. Renal disposition and drug interaction screening of (-)-2′-deoxy-3′-thiacytidine (3TC) in the isolated perfused rat kidney. Pharm Res 1995; 12: 1958-63
84. Linn JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1996; 23: 1008-21
85. Hinderung PH, Dilea C, Koziol T, et al. Comparative kinetics of sematilide in four species. Drug Metab Dispos 1993; 21: 662-9
86. Swabb E, Bonner D. Prediction of aztreonam pharmacokinetics in humans based on data from animals. J Pharmacokinet Biopharm 1983; 11: 215-23
87. Boxenbaum H, D'Souza RW. Interspecies pharmacokinetic scaling, biolgical design, and neoteny. In: Testa B, editor. Advances in drug research. London: Academic Press, 1991: 1-116
88. Sawada Y, Hanano M, Sugiyama Y, et al. Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J Pharmacokinet Biopharm 1984; 12: 587-46
89. Neilson P, Rasmussen F. Halflife and renal excretion of trimethoprim in swine. Acta Pharmacol Toxicol 1975; 36: 123-31
90. Burtin M, Elghozi I, Laude D, et al. Speciies differences in mammalian renal function: 5-HIAA, a reported marker of tubular secretion in humans, is handled exclusively by filtration in the rat. Exp Nephrol 1993; 1: 62-4
91. Rasmussen F. Renal clearance: species differences and similarities. Vet Res Commun 1983; 7: 301-6
92. Biggi A, Viglietti A, Farinelli MC, et al. Estimation of glomerular filtration using chromium-51 diamine tetra-acetic acid and technetium-99m diethylene triamine penta-acetic acid. Eur J Nucl Med 1995; 22: 532-6
93. Fleming JS, Wilkinson J, Oliver RM, et al. Comparison of radionuclide estimation of glomerular filtration using technetium-99m diethylenetriaminepentaacetic acid and chromium-51 ethylenediaminetetraacetic acid. Eur J Nucl Med 1991; 18: 391-5
94. Effersoe H, Rosenkilde P, Groth S, et al. Measurement of renal function with iohexol: a comparison of iohexol, 99m-Tc-DPTA. and 51Cr-EDTA clearance. Invest Radiol 1990; 25: 778-82
95. Frennby B. Use of iohexol clearance to determine glomerular filtration rate: a comparison between different clearance techniques in man and animal. Scand J Urol Nephrol 1997; 182 Suppl.: 1-63
96. Schuster VL, Seidin DW. Renal clearance. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathophysiology. Vol. I. New York: Raven Press, 1985: 365-95
97. Smith HW. The kidney: structure and function in health and disease. New York: Oxford University Press, 1951
98. Mujais SK, Quintanilla A, Zahid M, et al. Renal handling of enalaprilat. Am J Kidney Dis 1992; 19: 121-5
99. Reubi FC. Clearance tests in clinical medicine. Springfield: C.C. Thomas, 1963
100. Brod J, Sterzel RB. Conventional measurements for renal clearance measurements in man. Contrib Nephrol 1978; 11: 1-9
101. Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Ann Rev Med 1988; 39: 465-90
102. Lemmer B. Tagesrhyhtm and Arzneitittelwirkung. In: Lemmer B, editor. Chronopharmakokinetik. 2nd ed. Stutgart: Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 1984
103. Hull JH, Hak LJ, Kock GG. Influence of range of renal function and liver disease on predictability of renal clearance. Clin Pharmacol Ther 1981; 29: 516-21
104. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
105. Mawer EG, Knowles BR, Lucas SB, et al. Computer assisted prescribing of kanamycin for patients with renal insufficiency. Lancet 1972; 1: 12-5
106. Jelliffe RW. Creatinine clearance: a bedside estimate. Ann Intern Med 1973; 79: 604-5
107. Robertshaw M, Lai KN, Swaminathan R. Prediction of creatinine clearance from plasma: comparison of five formula. Br J Clin Pharmacol 1989; 28: 275-80
108. Luke DR, Halstenson CE, Opsahl JA, et al. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther 1990; 48: 503-8
109. Uhl S, Schmid P, Schlauer C. Pharmacokinetics of pentachlorophenol in man. Arch Toxicol 1986; 58: 182-6
110. Skoutakis VA. Clinical toxicology of drugs: principles and practice. Philadelphia: Lea & Febiger, 1982
111. Chiou WL. A new simple approach to study the effect of changes in urine flow and/or urine pH on renal clearance and its applications. Int J Clin Pharmacol Ther Toxicol 1986; 24: 519-27
112. Berndt A, Gramalte T, Oertel K, et al. Day-night variations in the renal excretion of the antiarrhythmic tiracizine and its metabolites. Chronobiol Int 1945; 12: 135-40
113. Gilman AG, Goodman LS, Rall TS, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. 7th ed. New York: MacMillan Publishing Company, 1985
114. Huff JW, Perzweig WA. N-1-methylnicotinamide, a metabolite of nicotinic acid in the urine. J Biol Chem 1943; 150: 395-400
115. Nasseri K, Daley-Yates PT. A comparison of N-1-methylnicotinamide clearance with five other markers of renal function in models of acute and chronic renal failure. Toxicol Lett 1990; 53: 231-45
116. Maiza A, Daley-Yates PT. Variability in the renal clearance of cephalexin in experimental renal failure. J Pharmacokinet Biopharm 1993; 21: 19-30
117. Somogyi A, Mclean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J C lin Pharmacol 1983; 25: 339-45
118. Dossing M, Pilsgaard H, Rasmussen B, et al. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol, 1983; 25: 215-22
119. Feely J, Wilkinson GR, Wood AJJ. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 1981; 304: 392-5
120. Feely J, Wilkinson GR, McAllister CB, et al. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med 1982; 96: 592-4
121. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 1981; 6: 135-51
122. Jaehde U, Sorgel F, Reiter A, et al. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 1995; 58: 532-41
123. Bauer L, Horn JR, Pettit H. Mixed-effect modeling for detection and evaluation of drug-drug interactions: digoxin-quinidine and digoxin-verapantil combinations. Ther Drug Monit 1996; 18: 46-52
124. Grasela TH, Antal RJ, Ereshefsky L, et al. An evaluation of population pharmacokinetics in therapeutic trials. II: detection of a drug-drug interaction. Clin Pharmacol Ther 1987; 42: 433-41
125. Sjostrom PA, Odlind BG, Wolgast M. Extensive tubular secretion and reabsorption of creatinine in humans. Scand J Urol Nephrol 1988; 22: 129-31
126. El-Tahtawy AA, Jackson AJ, Ludden TM, Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and monte carlo simulations. Pharm Res 1994; 11: 1330-6
127. Chow S-C, Liu J-P. Design and analysis of bioavailability and bioequivalence studies. New York: Marcell Dekker, 1992
128. Ratkowsky DA, Evans MA, Alldredge JR. Cross-over experiments: design, analysis and application. New York: Marcell Dekker, 1993